ICOS: Advanced Dyslipidemia Management for CV Risk Reduction

To explore how ICOS can assist your CV patients and connect you with a medical rep, please tick the box below:

I acknowledge that my contact details may be used for this purpose*

GGI-CO-A1-AQS-300040480-ELC-H24-1448
IPE: Icosapent ethyl; AHA: American Heart Association (AHA) Science Advisory 2020; NLA: National Lipid Association (NLA) Scientific Statement 2019; T2DM: Type 2 diabetes; CAD: Coronary Artery Disease; TG: Triglyceride; CVD: Cardiovascular Diseases; CV: Cardiovascular; LDL-C: Low-density lipoprotein-cholesterol
Reference:
1.	Bhatt DL, Steg PG, Miller M, et al; on behalf of the REDUCE-IT Investigators. Effects of icosapent ethyl on total ischemic events: from REDUCE-IT. J Am Coll Cardiol. 2019;73(22):2791-2802.

Persistent CV Risk in Elevated Triglycerides Despite Statin Therapy: ICOS Solution

Mr. Basu’s case: a 54-year-old patient with diabetes, hypertension, and hyperlipidemia on statins, evaluated with...

Explore Ram's case to see how ICOS lowers first, subsequent, and total CV events in...

Discover how ICOS, an NLA and AHA-endorsed option, supports improved CV outcomes in patients with...

Heart Meds Cut Risks, Spark GI Issues Now!

@media (max-width:992px) and (min-width:768px) {}         @media (max-width:767px)...